Christian Griesinger

This inventor holds 7 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignees: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , Ludwig-Maximilians-Universitat München. Active years: 2014-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christian Griesinger. Retrieved from https://idiyas.com/inventor/christian-griesinger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 6(Granted Patents)

Location History:

Goettingen, DE (2014 - 2016)
Göttingen, DE (2018 - 2021)

Company Filing History:

7 out of 1,334

Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V.

patents

3 out of 50

Ludwig-Maximilians-Universitat München

patents

where one patent can have more than one assignee

Years Active: 2014-2021

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11180518 - Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma (2021-11-23),

2. 10435373 - Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases (2019-10-08),

3. 10308671 - Water-soluble derivatives of 3,5-diphenyl-diazole compounds (2019-06-04),

4. 10071966 - Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases (2018-09-11),

5. 9253964 - Mutant alpha-synuclein, and methods using same (2016-02-09),

6. 9247721 - Transgenic non-human animal comprising a mutant alpha-synuclein (2016-02-02),

7. 8809505 - Mutant alpha-synuclein, and methods using same (2014-08-19),

Title: Christian Griesinger: Innovator in Pharmaceutical Chemistry

Introduction

Christian Griesinger is a notable inventor based in Göttingen, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds for treating serious medical conditions. With a total of 7 patents to his name, Griesinger's work is recognized for its potential impact on healthcare.

Latest Patents

Among his latest patents, Griesinger has developed phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma. This invention relates to a compound represented by the formula (E), which is useful for treating or preventing this aggressive form of skin cancer. Additionally, he has created a drug aimed at inhibiting the aggregation of proteins involved in diseases linked to protein aggregation and neurodegenerative diseases. This invention also pertains to a compound represented by formula (E) and includes pharmaceutical and diagnostic compositions, as well as methods for imaging deposits of aggregated protein.

Career Highlights

Throughout his career, Griesinger has been associated with prestigious institutions such as the Max Planck Society for the Advancement of Science and Ludwig Maximilian University of Munich. His work in these organizations has allowed him to push the boundaries of research in pharmaceutical applications.

Collaborations

Griesinger has collaborated with notable colleagues, including Armin Giese and Andrei Leonov. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Christian Griesinger stands out as an influential inventor in the realm of pharmaceutical chemistry. His innovative patents and collaborations reflect his commitment to advancing medical science and improving treatment options for patients.

Profile summary based on public USPTO records.